Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Netarsudil for Proliferative Vitreoretinopathy Prevention
NCT06033703Phase 2Recruiting
- Sponsor
- Massachusetts Eye and Ear
- Start
- Jan 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of netarsudil in rhegmatogenous retinal detachment (RRD), Proliferative Vitreoretinopathy (PVR), sponsored by Massachusetts Eye and Ear. Started Jan 2025; status: recruiting.
02
Drugs
netarsudil
03
Conditions
rhegmatogenous retinal detachment (RRD)Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT06033703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033703.